首页 | 本学科首页   官方微博 | 高级检索  
     


Phase 1b trial of isatuximab,an anti-CD38 monoclonal antibody,in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Authors:Thomas G. Martin MD  Nina Shah MD  Joshua Richter MD  David H. Vesole MD  Sandy W. Wong MD  Chiung-Yu Huang PhD  Deepu Madduri MD  Sundar Jagannath MD  David S. Siegel MD  Noa Biran MD  Jeffrey L. Wolf MD  Samir Parekh MD  Hearn J. Cho MD  PhD  Pamela Munster MD  Shambavi Richard MD  Samira Ziti-Ljajic MSc  Ajai Chari MD
Affiliation:1. Hematology/Oncology, University of California San Francisco Medical Center, San Francisco, California;2. Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, New York;3. Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey;4. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California;5. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York;6. Translational Medicine and Early Development, Pharmacokinetic and Drug Metabolism, Pharmacokinetic Unit, Sanofi, Paris, France
Abstract:
Keywords:carfilzomib  isatuximab  immunomodulatory  monoclonal antibody  pharmacokinetics  proteasome
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号